Physician profile
John M Brown
NPI 1952490153
$3,791.27
in general payments reported to CMS, 2019-2025
36 companies · $581 in 2025
The $581 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $701 · 2020: $392 · 2021: $509 · 2022: $200 · 2023: $679 · 2024: $729 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,988.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $383.48 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Lilly USA, LLC | $325.14 | 2019-2025 | Mounjaro, Zepbound |
| Corium, LLC | $308.36 | 2022-2025 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.59 | 2019-2023 | Spiriva Respimat, Jardiance |
| Amgen INC. | $284.03 | 2019-2024 | Repatha, Otezla |
| Abbvie INC. | $243.74 | 2021-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $233.88 | 2019-2025 | |
| Adlon Therapeutics L.P. | $176.59 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $166.63 | 2019-2025 | Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $151.60 | 2019-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Novartis Pharmaceuticals Corporation | $134.44 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.66 | 2023-2025 | Caplyta |
| Novo Nordisk INC | $97.39 | 2021-2025 | Wegovy |
| Exact Sciences Corporation | $87.04 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company Ltd. | $83.31 | 2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.